Sellas Life Sciences Group, INC 8-K filings

SELLAS Life Sciences has announced a restructuring of its executive leadership, including the departure of two key executives, to prioritize clinical programs and commercialization partnerships.

SELLAS Life Sciences Group has regained compliance with Nasdaq's minimum market value requirement after its stock maintained a value above $35 million for ten consecutive days.

SELLAS Life Sciences Group has been notified by Nasdaq that its stock price has fallen below the minimum bid price requirement, triggering a 180-day grace period to regain compliance.